Blood cancers

How MRD negativity analysis will influence the therapeutic landscape for multiple myeloma

Sponsored by Amgen Australia Pty Ltd

We sat down with Professor Andrew Spencer, head of the malignant haematology and stem cell transplantation service at The Alfred Hospital, Melbourne, to ask his thoughts on the impact of MRD negativity analysis on future trial design and clinical decision-making. He also offered his perspective on the importance of moving to a more personalised treatment ...

Already a member?

Login to keep reading.

© 2021 the limbic